Trials / Unknown
UnknownNCT04782128
Evaluation of RC28-E Injection in Diabetic Retinopathy
A Randomized, Open-label, Multicenter Study of the Efficacy and Safety of RC28-E Injection in Subjects With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RC28-E injection | a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF |
Timeline
- Start date
- 2021-05-25
- Primary completion
- 2024-05-01
- Completion
- 2024-07-01
- First posted
- 2021-03-04
- Last updated
- 2023-10-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04782128. Inclusion in this directory is not an endorsement.